NIH-funded research Sbir 1 grant

A new antibody to support brain health and growth in Alzheimer's patients

Official title: A Novel Antibody that Promotes Neuronal Integrity and Neurogenesis for Treating Alzheimer's Disease

Funded at Virtici, LLC · NIH-10893118 · Data updated 2026-11-12

This study is testing a new treatment that uses a special type of antibody to help protect brain cells and encourage the growth of new ones in people with Alzheimer's Disease, with the hope of improving brain function and reducing harmful proteins.

More s Disease research and trials

Quick facts

Grant typeSbir 1 grant
Study typeNIH-funded research
Funding institutionVirtici, LLC
NIH-funded
Lab location1 site (Seattle, UNITED STATES)
Project startSeptember 30, 2022
Project endAugust 31, 2025
Funding year2023
Award (this year)$257,417
NIH project number3R43AG080879-02S1
Project IDNIH-10893118 on NIH RePORTER

Who could benefit from this research

Could help

Ideal candidates for this research are individuals diagnosed with Alzheimer's Disease or those exhibiting early signs of cognitive decline.

Less likely to help

Patients with other forms of dementia unrelated to Alzheimer's Disease may not benefit from this research.

What this research studies

This research focuses on developing a unique bispecific antibody designed to enhance neuronal integrity and promote the growth of new neurons in individuals with Alzheimer's Disease (AD). The approach involves targeting specific proteins in the brain that are linked to the progression of AD, aiming to reduce harmful protein accumulation and improve brain function. By utilizing advanced antibody technology, the research seeks to create a treatment that could potentially reverse some of the damaging effects of AD. Patients may be involved in trials to assess the safety and effectiveness of this innovative therapy.

Why it matters

Potential benefit: If successful, this research could lead to a groundbreaking treatment that not only alleviates symptoms of Alzheimer's Disease but also promotes brain health and regeneration.

How similar studies have gone: While there have been various approaches to treating Alzheimer's, this specific bispecific antibody strategy is novel and has not been extensively tested in previous studies.

Where this research is happening

  • Virtici, LLC
    Seattle, United States
    Active

Researchers

  • Principal investigator: Fanger, Neil a — Virtici, LLC
  • Study coordinator: Fanger, Neil a

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.